Clinical Trial Update: Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety, tolerability, and efficacy of cilofexor (GS-9674) in nonalcoholic steatohepatitis has completed with results posted in 2019…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• cilofexor (GS-9674) (cilofexor)

Snippet

Sponsor: Gilead Sciences | Conditions: Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED | Results posted: 2019-01-29